Replimune Group, Inc. (REPL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 10.19 |
| Open | 10.2 |
| Day High | 11.43 |
| Day Low | 10.19 |
| 52-Week High | 13.24 |
| 52-Week Low | 1.5 |
| Volume | 3.08M |
| Average Volume | 7.64M |
| Market Cap | 923.16M |
| PE | -3.25 |
| EPS | -3.44 |
| Moving Average 50 Days | 5.35 |
| Moving Average 200 Days | 7.08 |
| Change | 0.99 |
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management te
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
GlobeNewswire Inc.
Nov 07, 2025 9:45 PM GMT
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failureWOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncoly